CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival

Neoplasma

Volumn 57, Issue 1, 2010, Pages 15-19

  Vrana, D ^a,b,c   Novotny, J ^b   Holcatova, I ^b   Hlavata, I ^b,c   Soucek, P ^a  

^a Nemocnice Atlas   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

CYP1B1; Pancreatic cancer; Polymorphism; Risk; Survival

Indexed keywords

CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450;

ADULT; AGED; ARTICLE; CODON; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; RISK;

ADULT; AGED; CODON; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; RISK;

EID: 77953635345     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2010_01_015     Document Type: Article

References (22)

1. Cancer Incidence 2005 in the Czech Republic, IHIS CR, NOR CR, Czech Republic 2008, p 62.
2. Shimada T, Gillam EM, Oda Y, Tsumura F, Sutter TR et al. Metabolism of benzo [a]pyrene to trans-7,8-dihy-droxy-7,8-dihydrobenzo [a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem Res Toxicol 1999; 12: 623-9. doi:10.1021/tx990028s
3. Kim JH, Standbury KH, Walker NJ, Trush MA, Strickland PT, et al. Metabolism of benzo [a]pyrene and benzo [a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1998; 19: 1847-53. doi:10.1093/carcin/19.10.1847
4. Rodrigues-Antona C, Ingelman-Sundeberg M. Cytochrome P450 pharmacogenetics and cancer, Oncogene 2006; 25: 1679-91. doi:10.1038/sj.onc.1209377
5. Bethke L, Webb E, Sellick G, Rudd M, Penegar S, et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer 2007; 7: 123. doi:10.1186/1471-2407-7-123
6. Wu MF, Wu WJ, Chang GC, Chen CY, Hu SW, et al. Increased expression of cytochrome P4501B1 in peripheral leukocytes from lung cancer patients. Toxicol Lett 2004; 150: 211-9. doi:10.1016/j.toxlet.2004.01.006
7. Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003; 89: 1524-29. doi:10.1038/sj.bjc.6601288
8. Sasaki M, Masahiro Y, Okino, ST, Mitsuharu N, Suguru Y, et al. Polymorphisms of the CYP1B1 Gene as Risk Factors for Human Renal Cell Cancer. Clin Cancer Res 2004; 10: 2015-19. doi:10.1158/1078-0432.CCR-03-0166
9. Ko Y, Abel J, Harth W, Brode P, Antony C, et al. Association of CYP1B1 Codon 432 Mutant Allele in Head and Neck Squamous Cell Cancer Is Reflected by Somatic Mutations of p53 in Tumor Tissue. Cancer Res 2001; 61: 4398-4404.
10. Crous-Bou M, De Vivo I, Porta M, Pumarega JA, Lopez T, et al. CYP1B1 Polymorphisms and K-ras Mutations in Patients with Pancreatic Ductal Adenocarcinoma. Dig Dis Sci 2008; 53: 1417-21. doi:10.1007/s10620-008-0235-9
11. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=1545)
12. Stoilov I, Akarsu AN, Alozie I, Child A, Bar-Soum-Homsy M, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998; 62: 573-584. doi:10.1086/301764
13. Hanna IM, Dawling S, Roodi N, Guengerich FP, Parl FF, et al. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Research 2000; 60: 3440-344.
14. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996; 56: 2979-2984
15. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM,et al. Specificity of 17beta-oestradiol and benzo [a]pyrene oxidation by polymorphic cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica. 2001; 31: 163-176. doi:10.1080/ 00498250110043490
16. Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, et al. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis 1990; 11: 1527-30. doi:10.1093/carcin/11.9.1527
17. Ketelslegers HB, Godschalk RW, Eskens BJ, Dallin-Ga JW, Gottschalk RW, et al. Potential role of cytochrome P450-1B1 in the metabolic activation of 4-aminobiphenyl in humans. Mol Carcinog 2009 Mar 9. [Epub ahead of print].
18. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM, et al. Specificity of 17beta-oestradiol and benzo [a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica. 2001; 31: 163-76. doi:10.1080/00498250110043490
19. Paracchini V, Raimondi S, Gram IT, Kang D, KOCABAS NA, et al. Meta-and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 2007; 165: 115-25. doi:10.1093/aje/kwj365
20. Lee HC, Yoon YB, Kim CY Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer. The Korean Journal of Internal Medicine 1997; 12: 128-36.
21. Li D, Jiao L, Li Y, Doll MA, Hein DW, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006; 27: 103-11. doi:10.1093/carcin/bgi171
22. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008; 29: 1184-91. doi:10.1093/carcin/bgn085 04ioann